Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	20.74B +5.3%
Revenue (ttm)	2.10B -17.5%
Net Income	188.77M +1,178.9%
EPS	0.12 +1,163.9%
Shares Out	1.60B
PE Ratio	110.53
Forward PE	n/a
Dividend	0.16 (1.18%)
Ex-Dividend Date	Jun 24, 2026

Volume	43,412,992
Open	13.21
Previous Close	13.01
Day's Range	12.83 - 13.21
52-Week Range	10.88 - 16.97
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,981
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error